Greenwoods Asset Management Hong Kong Ltd. lessened its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 87.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 68,265 shares of the exchange traded fund’s stock after selling 486,750 shares during the period. SPDR S&P Biotech ETF comprises approximately 0.2% of Greenwoods Asset Management Hong Kong Ltd.’s investment portfolio, making the stock its 26th biggest holding. Greenwoods Asset Management Hong Kong Ltd. owned approximately 0.10% of SPDR S&P Biotech ETF worth $8,324,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. PNC Financial Services Group Inc. increased its stake in shares of SPDR S&P Biotech ETF by 3.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 72,695 shares of the exchange traded fund’s stock valued at $8,864,000 after buying an additional 2,168 shares during the period. Arrow Financial Corp bought a new position in SPDR S&P Biotech ETF during the 4th quarter worth about $207,000. Millennium Capital Advisors LLC purchased a new position in SPDR S&P Biotech ETF during the 4th quarter valued at about $576,000. AlphaCore Capital LLC increased its position in SPDR S&P Biotech ETF by 1,638.6% during the 4th quarter. AlphaCore Capital LLC now owns 7,650 shares of the exchange traded fund’s stock valued at $933,000 after purchasing an additional 7,210 shares during the period. Finally, Bessemer Group Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 13.5% in the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock valued at $225,965,000 after purchasing an additional 220,244 shares in the last quarter.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $126.79 on Wednesday. The company has a market cap of $8.09 billion, a PE ratio of 11.47 and a beta of 0.85. The firm’s 50 day moving average price is $129.52 and its 200-day moving average price is $124.72. SPDR S&P Biotech ETF has a 52-week low of $78.00 and a 52-week high of $139.19.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
